Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and upregulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D 3

Cell Cycle

Volumn 9, Issue 22, 2010, Pages 4542-4551

  Wang, Xuening ^a   Gocek, Elzbieta ^a,b   Novik, Victoria ^c   Harrison, Jonathan S ^d   Danilenko, Michael ^c   Studzinski, George P ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WROC AW   (Poland)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Cot1 oncogene; ERK5; MAPK signaling; Plant antioxidants; Silibinin; Vitamin D

Indexed keywords

CALCITRIOL; COT1 ENZYME; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MITOGEN ACTIVATED PROTEIN KINASE 7; PROTEIN KINASE; SILIBININ; SMALL INTERFERING RNA; TLP2 ENZYME; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CLINICAL ARTICLE; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MALE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION;

EID: 78649843971     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.22.13790     Document Type: Article

References (60)

1. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2008; 7176.
2. Bardia A, Tleyjeh IM, Cerhan JR, Sood AK, Limburg PJ, Erwin PJ, et al. Efficacy of antioxidant supplementation in reducing primary cancer incidence and mortality: systematic review and meta-analysis. Mayo Clin Proc 2008; 83:23-34.
3. Dotan Y, Lichtenberg D, Pinchuk I. No evidence supports vitamin E indiscriminate supplementation. Biofactors 2009; 35:469-73.
4. Greenlee H, Hershman DL, Jacobson JS. Use of antioxidant supplements during breast cancer treatment: a comprehensive review. Breast Cancer Res Treat 2009; 115:437-52.
5. Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 1998; 93:139-43.
6. Haddad Y, Vallerand D, Brault A, Haddad PS. Antioxidant and Hepatoprotective Effects of Silibinin in a Rat Model of Nonalcoholic Steatohepatitis. Evid Based Complement Alternat Med 2009; In press.
7. Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, Liu Y, et al. Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci USA 2010; 107:5995-9.
8. Neumann UP, Biermer M, Eurich D, Neuhaus P, Berg T. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol 2010; 52:951-2.
9. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res 2010; 4:1423-32.
10. Singh RP, Agarwal R. Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog 2006; 45:436-42.
11. Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett 2008; 269:352-62.
12. Cheung CW, Gibbons N, Johnson DW, Nicol DL. Silibinin-a promising new treatment for cancer. Anticancer Agents Med Chem 2010; 10:186-95.
13. 3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium. Cancer Res 2003; 63:1325-32.
14. 3 in induction of leukemia HL60 cell differentiation through the JNK/AP-1/Egr-1 pathway. J Cell Physiol 2005; 204:964-74.
15. 3-induced differentiation of human AML cells ex vivo and regulates the levels of differentiation-related transcription factors. Hematol Oncol 2010; 28:124-32.
16. Pesakhov S, Khanin M, Studzinski GP, Danilenko M. Distinct combinatorial effects of the plant polyphenols curcumin, carnosic acid and silibinin on proliferation and apoptosis in acute myeloid leukemia cells. Nutr Cancer 2010; 62:811-24.
17. 3 and antioxidants. Cancer Biol Ther 2010; 10:344-50.
18. Osborn JL, Schwartz GG, Smith DC, Bahnson R, Day R, Trump DL. Phase II Trial of Oral 1,25-Dihydroxyvitamin D (Calcitriol) in Hormone Refractory Prostate Cancer. Urol Oncol: Seminars and Original Investigations 1995; 1:195-8.
19. Beer TM, Munar M, Henner WD. A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 2001; 91:2431-9.
20. Chadha MK, Tian L, Mashtare T, Payne V, Silliman C, Levine E, et al. Phase 2 trial of weekly intravenous 1,25-dihydroxy-cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. Cancer 2010; 116:2132-9.
21. 3 and its analogs. Exp Cell Res 2004; 298:339-58.
22. 3-induced differentiation of human leukemia HL60 cells. Exp Cell Res 2000; 258:425-37.
23. 3 activate three MAPK pathways and upregulate pRb expression in differentiating HL60 cells. Cell Cycle 2002; 1:410-5.
24. Zhang J, Posner GH, Danilenko M, Studzinski GP. Differentiation-inducing potency of the seco-steroid JK-1624F2-2 can be increased by combination with an antioxidant and a p38MAPK inhibitor which upregulates the JNK pathway. J Steroid Biochem Mol Biol 2007; 105:140-9.
25. Salmeron A, Ahmad TB, Carlile GW, Pappin D, Narsimhan RP, Ley SC. Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase. EMBO J 1996; 15:817-26.
26. Hagemann D, Troppmair J, Rapp UR. Cot protooncoprotein activates the dual specificity kinases MEK-1 and SEK-1 and induces differentiation of PC12 cells. Oncogene 1999; 18:1391-400.
27. Chiariello M, Marinissen MJ, Gutkind JS. Multiple mitogen-activated protein kinase signaling pathways connect the cot oncoprotein to the c-jun promoter and to cellular transformation. Mol Cell Biol 2000; 20:1747-58.
28. Luciano BS, Hsu S, Channavajhala PL, Lin LL, Cuozzo JW. Phosphorylation of threonine 290 in the activation loop of Tpl2/Cot is necessary but not sufficient for kinase activity. J Biol Chem 2004; 279:52117-23.
29. Channavajhala PL, Rao VR, Spaulding V, Lin LL, Zhang YG. hKSR-2 inhibits MEKK3-activated MAP kinase and NFkappaB pathways in inflammation. Biochem Biophys Res Commun 2005; 334:1214-8.
30. 3-Induced Differentiation of Human Acute Myeloid Leukemia Cells. J Cell Physiol 2010; [Epub ahead of print].
31. 3. J Cell Physiol 2004; 198:333-42.
32. 3-induced differentiation of HL60 cells but is not mediated by the MEK/ERK module. J Cell Physiol 2006; 209:253-60.
33. 3 and is required for optimal cell differentiation. Exp Cell Res 2007; 313:3034-45.
34. 3 in parallel with activated c-jun during differentiation of human myeloid leukemia cells. J Steroid Biochem Mol Biol 2010; 121:395-8.
35. Koeffler HP, Billing R, Lusis AJ, Sparkes R, Golde DW. An undifferentiated variant derived from the human acute myelogenous leukemia cell line (KG-1). Blood 1980; 56:265-73.
36. Koeffler HP. Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood 1983; 62:709-21.
37. Manzel L, Macfarlane DE. Protein kinase C is not necessary for transforming growth factor beta-induced growth-arrest in leukemia cell lines. Leuk Res 1997; 21:403-10.
38. 3 and its 20-epi analog integrates clonal expansion, maturation and apoptosis during HL-60 cell differentiation. Mol Cell Endocrinol 1999; 149:169-83.
39. 3-induced differentiation of AML cells carrying various mutations. Leuk Res 2010; 34:649-57.
40. Chan AM, Chedid M, McGovern ES, Popescu NC, Miki T, Aaronson SA. Expression cDNA cloning of a serine kinase transforming gene. Oncogene 1993; 8:1329-33.
41. Aoki M, Hamada F, Sugimoto T, Sumida S, Akiyama T, Toyoshima K. The human cot proto-oncogene encodes two protein serine/threonine kinases with different transforming activities by alternative initiation of translation. J Biol Chem 1993; 268:22723-32.
42. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American- British (FAB) co-operative group. Br J Haematol 1976; 33:451-8.
43. Blagosklonny MV, Pardee AB. The restriction point of the cell cycle. Cell Cycle 2002; 1:103-10.
44. 3 in HL60 cells. Cancer Res 1996; 56:264-7.
45. Rovida E, Spinelli E, Sdelci S, Barbetti V, Morandi A, Giuntoli S, et al. ERK5/BMK1 is indispensable for optimal colony-stimulating factor 1 (CSF-1)-induced proliferation in macrophages in a Src-dependent fashion. J Immunol 2008; 180:4166-72.
46. Roy S, Kaur M, Agarwal C, Tecklenburg M, Sclafani RA, Agarwal R. p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther 2007; 6:2696-707.
47. 3 and participates in its anti-apoptotic effect and cell cycle control in differentiating HL60 cells. Cell Cycle 2006; 5:447-51.
48. 3. Cell Cycle 2009; 8:736-41.
49. Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee JD. Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 1998; 395:713-6.
50. Buzzi N, Colicheo A, Boland R, de Boland AR. MAP kinases in proliferating human colon cancer Caco-2 cells. Mol Cell Biochem 2009; 328:201-8.
51. Inesta-Vaquera FA, Campbell DG, Tournier C, Gomez N, Lizcano JM, Cuenda A. Alternative ERK5 regulation by phosphorylation during the cell cycle. Cell Signal 2010; 22:1829-37.
52. Tyagi A, Singh RP, Ramasamy K, Raina K, Redente EF, Dwyer-Nield LD, et al. Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factorkappaB and signal transducers and activators of transcription 3. Cancer Prev Res (Phila) 2009; 2:74-83.
53. Wu K, Zeng J, Li L, Fan J, Zhang D, Xue Y, et al. Silibinin reverses epithelial-to-mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors. Oncol Rep 2010; 23:1545-52.
54. Velmurugan B, Gangar SC, Kaur M, Tyagi A, Deep G, Agarwal R. Silibinin Exerts Sustained Growth Suppressive Effect against Human Colon Carcinoma SW480 Xenograft by Targeting Multiple Signaling Molecules. Pharm Res 2010; 27:2085-97.
55. Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev 2010; 29:447-63.
56. Kang SN, Lee MH, Kim KM, Cho D, Kim TS. Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by silibinin: involvement of protein kinase C. Biochem Pharmacol 2001; 61:1487-95.
57. Gavrin LK, Green N, Hu Y, Janz K, Kaila N, Li HQ, et al. Inhibition of Tpl2 kinase and TNFalpha production with 1,7-naphthyridine-3-carbonitriles: synthesis and structure-activity relationships. Bioorg Med Chem Lett 2005; 15:5288-92.
58. Hu Y, Green N, Gavrin LK, Janz K, Kaila N, Li HQ, et al. Inhibition of Tpl2 kinase and TNFalpha production with quinoline-3-carbonitriles for the treatment of rheumatoid arthritis. Bioorg Med Chem Lett 2006; 16:6067-72.
59. Hirata K, Taki H, Shinoda K, Hounoki H, Miyahara T, Tobe K, et al. Inhibition of tumor progression locus 2 protein kinase suppresses receptor activator of nuclear factor-kappaB ligand-induced osteoclastogenesis through downregulation of the c-Fos and nuclear factor of activated T cells c1 genes. Biol Pharm Bull 2010; 33:133-7.
60. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980; 26:171-6.